Dynamic Cross Linking (DXL™) technology seeks to improve upon the therapeutic potency of the second generation of "humanized" monoclonal antibody products by increasing target antigen binding, enhancing antibody effector functions, and installing new properties into antibodies such as the ability to trigger apoptosis, or "cell suicide". Put simply, DXL™ allows antibodies to achieve a higher level of therapeutic usefulness.
The target market for licensing of DXL™ is established pharmaceutical and biotechnology companies that wish to utilize DXL™ to improve upon the effectiveness of their existing monoclonal antibody-based products. Industry sources estimate that there are currently 260 biotechnology companies worldwide involved in the development of at least 700 antibody-based products.
How DXL Works
Conventional antibodies bind to their targets with only one arm each. DXL™ antibodies bind to their targets in the same manner as conventional antibodies. Unlike conventional antibodies, DXL™ antibodies can also bind to each other. When DXL™ antibodies bind to each other, as illustrated below, the result is increased antibody binding strength and potency.
